Cellino Biotech, Inc.

Active dates:

May 3, 2019 - May 3, 2019
STEX25 Participation:
May 3, 2019 - October 30, 2020
Company information

501 Massachusetts Ave. (The Engine)
Cambridge, MA 02139
United States

Elevator Pitch

Elevator Pitch

Cellino uses the latest advances in image-based machine learning to take actionable steps on cells undergoing differentiation. The hardware/software platform is the first to manufacture human-like tissues with high functionality and structure for the tissue replacement industry. The first area of focus is the manufacturing of transplantable retinal pigment epithelial cells to restore sight in patients suffering from vision loss.


Cellino has built the first platform that enables precise control over iPS cell fate in their natural environment. Their proprietary delivery technology, NanoLaze, delivers synthetic biology tools to control the sequence of genes being turned on and off inside a cell. This offers precise, “digital” control over cell fate. The technology steers iPS cells to a target cell state, creating any mature cell at will. Need healthy neurons? Or kidney cells? Whatever the cell type, Cellino’s platform has the potential to create them.

Cellino’s platform is 10x faster at writing programs to make functionally mature cells that are critical for clinical therapies. That means that more cell types can be created, more successfully, at a speed that makes them useful for dozens of shots on goal for cell therapies. It is a technology that will help us heal ourselves, faster. Cellino intentionally design mixed populations of cells to improve tissue interconnectivity and engraftment.
Technology Description

Technology Description

Cellino is engineering human-like cells and tissues for replacement therapies.